Case Summary

Reckitt Benckiser Group

OTC BB: RBGLY

Case Details

  • Elevator Constructors Union Local No. 1 Annuity & 401(k) Fund v. Reckitt Benckiser Group plc et al.
  • Class Period:January 13, 2021 - July 28, 2024
  • Date Filed:June 05, 2025
  • Jurisdiction:U.S. District Court, Southern District of New York
  • Docket Number: 1:25-cv-04708
  • Lead Plaintiff Deadline: August 4, 2025
Days Left to
Seek Plaintiff
30

Overview

A class action lawsuit has been filed against Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) and certain of the Company’s current and former officers and executives (collectively, “Defendants”) alleging violations of the federal securities laws.

The Reckitt class action lawsuit was brought on behalf of all persons and entities that purchased or otherwise acquired Reckitt American Depositary Shares (“ADSs”) between January 13, 2021, and July 28, 2024, inclusive (the “Class Period”).

Reckitt’s ordinary shares trade on the London Stock Exchange under the ticker symbol “RB,” while its sponsored ADSs trade on the U.S. over-the-counter (“OTC”) market under the ticker symbol “RBGLY.”

Reckitt, a United Kingdom (“U.K.”)-based global consumer goods company, reports three operating segments: (1) Hygiene, (2) Health, and (3) Nutrition. In 2017, Reckitt acquired Mead Johnson Nutrition (“Mead Johnson”) for $19.7 billion, which effectively provided the Company with its current Nutrition segment. Reckitt’s Nutrition segment includes, among others, its infant and child nutrition businesses, its adult nutrition, and its range of vitamins, minerals, and supplements. Reckitt’s Nutrition segment includes brands of infant and baby formulas, such as Enfamil. Enfamil is a cow’s milk-based formula designed to for bulking up premature infants quickly. In recent years, science and research have confirmed strong links between cow-based products and Necrotizing Enterocolitis (“NEC”) causing and/or substantially contributing to death in preterm and severely preterm, low-weight infants, along with many other health complications and long-term risks to these babies. Throughout the Class Period, Defendants touted the purportedly conclusive science on which Enfamil is based to assure investors and consumers of Enfamil’s safety.

Unbeknownst to investors, Reckitt failed to warn investors and consumers (1) that preterm infants were at an increased risk of developing NEC by consuming Reckitt’s cow’s milk-based formula, Enfamil; (2) of the attendant impact on Reckitt’s sales of Enfamil and Reckitt’s exposure to legal claims; and (3) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times

*          *          *

If you purchased or otherwise acquired Reckitt securities between January 13, 2021, and July 28, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as lead plaintiff in the Reckitt class action lawsuit is August 4, 2025.

Join This Action

Name(Required)
Address(Required)
Are you a current or former employee at the company?(Required)

Purchases

Purchases Buy Date Quantity Purchase Price per share or security Actions
There are no Purchases.

Sales

Sale Type Sale Date Quantity Sale Price per share or security Actions
There are no Sales.

Upload Documents

Drop files here or
Accepted file types: xls, xlsx, doc, pdf, jpg, jpeg, Max. file size: 50 MB, Max. files: 5.